Abstract DP355: Ferroptosis inhibitor UAMC-3203 preserves memory and prevents anxiety-like behavior but worsens aversive learning in diabetic rats after stroke: A randomized double-blind preclinical trial

Diabetes increases post-stroke mortality and cognitive impairment (PCSI). We previously demonstrated that iron chelation during the subacute phase enhances cognitive outcomes after stroke in experimental diabetes. Here, we hypothesized that inhibition of ferroptosis (iron-induced cell death) would prevent PSCI in diabetic animals. Diabetic male rats underwent sham or 60-min middle cerebral artery occlusion surgery. On Day 3 post-stroke, animals meeting inclusion criteria (adhesive removal >35 s on Day 3, Bederson score ≤6 on Day 0, or weight loss >10% on Day 1) were randomized to the ferroptosis inhibitor UAMC-3203 (2 mg/kg) or vehicle for 2 weeks (n=8–12/group). MRI confirmed stroke induction in >95% of animals. Data points are shown in Table 1. Animals developed episodic and spatial memory deficits after stroke and UAMC-3203 treatment prevented this decline. All animals showed anxiety-like behavior even at baseline, and this behavior was reversed only in the stroke treatment group. Interestingly, step-through latency in the passive avoidance test showed that stroke does not affect learning in vehicle-treated diabetic animals; however, the latency was lower in the stroke treatment group, suggesting inhibition of ferroptosis impairs aversive learning after stroke. At the molecular level, lipid peroxidation (4-HNE levels) was amplified after stroke. UAMC-3203 prevented this increase and preserved antioxidant GPX-4 protein levels. Our findings provide evidence that ferroptosis contributes to the development of progressive cognitive decline in memory functions after stroke in diabetes, and prevention of ferroptosis by a third-generation ferroptosis inhibitor is beneficial, but the adverse effect of treatment on aversive learning warrants further investigation.